Ivermectin, Fenbendazole and Tagrisso for Lung Cancer (6 Anonymized 2026 Case Reports)

Published by: Dr William Makis on X.com | Edited and Reviewed by: OneDayMD Editorial Team

Important Medical Disclaimer

This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Repurposed drugs like ivermectin and fenbendazole are not approved by the FDA or any major regulatory body for cancer. Self-medication can cause serious side effects including liver toxicity, drug interactions, or delayed standard care. Always consult a qualified oncologist before considering any off-label protocol. Individual results vary widely and often reflect combined therapies. The case below is anonymized from a publicly shared patient report; outcomes are not guaranteed.


Case Presentations

Case 1 - 2026: 63 year old woman in URUGUAY with Lung Cancer Recurrence reports after 5 months: No evidence of disease (NED)

Dr William Makis posted on X.com in August 2026:

IVERMECTIN and MEBENDAZOLE Testimonial - 63 year old woman in URUGUAY with Lung Cancer Recurrence reports after 5 months: No evidence of disease! Ivermectin Cancer revolution has made it all the way to Uruguay! STORY: 63 year old woman in URUGUAY with Lung Cancer Recurrence In December 2025 she started:
  • Ivermectin 1mg/kg/day
  • Mebendazole 1500mg/day
  • CBD Oil 100mg/day
  • Oncologist: Tagrisso*.
Results after 5 months: Cancer Free! "I had a CT scan and they told me I was clear, just the scars where the tumors had been". Repurposed Drug Research: Hundreds of published papers show evidence that repurposed anti-parasitics have treatment synergy with a wide variety of conventional Oncology treatments. Treatment synergy is the concept that two or more therapies interact and that combined effect is greater than the simple sum of each treatment used alone. Oncologists don't understand Treatment Synergy and are not allowed to explore it, because it undermines a multi-billion dollar Cancer drug business. Tagrisso alone brings in $7.25 billion a year for AstraZeneca and is one of their top selling drugs. Now imagine there was something out there, available for 8 to 15 cents a pill, that makes Tagrisso work so much better!

*Note: Tagrisso (osimertinib) is a third-generation epidermal growth factor receptor (EGFR-TKI) tyrosine kinase inhibitor.

Case 2 - 2026: 54-year-old woman with Stage IV Non-Small-Cell Lung Cancer (commonly described as NSCLC) with soft tissue metastases

Dr William Makis published this case on X.com in May 2026.

“Patient C.” is a 54-year-old woman diagnosed in July 2025 with Stage IV lung cancer (publicly described as NSCLC) with soft tissue metastases. The primary tumor measured 6.4 × 5.3 cm with SUVmax 9.5 on PET-CT. She also had intrathoracic lymph node metastases (up to 3.4 cm) and multiple soft tissue lesions. After starting conventional targeted therapy, she added repurposed agents under medical supervision.

The Protocol Used (August 2025 onward)

- Ivermectin + Fenbendazole: Added as repurposed agents (exact dosing not publicly detailed; managed privately).  

- Tagrisso (osimertinib): Standard targeted EGFR inhibitor continued as the backbone therapy.  

- Supportive measures (noted in follow-up reports): Brief pauses for monitoring, high-dose vitamin C IVs, and other supplements.  

- Monitoring: Serial whole-body PET-CT scans, bloodwork, and oncologist oversight. She had also received radiation to bone sites earlier in her course.  

The patient continued this integrated approach for 8 months.

Timeline & Outcomes (Anonymized Reports from Shared PET-CT)

- Baseline (July 2025): Primary right upper lobe mass 6.4 × 5.3 cm, SUVmax 9.5; multiple intrathoracic lymph nodes and soft tissue metastases.  

- December 2025 (≈4 months): Primary mass reduced to 3.5 × 2.3 cm, SUVmax 2.5; nodal and soft tissue lesions showed marked improvement.  

- March 2025 (≈8 months): Primary mass further reduced to 2.9 × 2.1 cm, SUVmax 2.4 (now at background level); all intrathoracic lymph node metastases resolved (100%); soft tissue metastases resolved (100%). No new lesions. The residual mass was described as centrally necrotic and metabolically inactive.  

Publicly shared imaging reports confirm “excellent near-complete metabolic treatment response” with continued interval improvement between scans.



Note: This was not repurposed drugs alone. The dramatic response occurred in the setting of ongoing Tagrisso therapy plus supportive care — a pattern frequently seen in patient-reported outcomes involving metabolic and repurposed approaches.

Case 3 - 2026: 51 year old Engineer from CZECH REPUBLIC with Stage 4 NSCLC Lung Cancer

Dr William Makis posted on X.com in February 2026:

IVERMECTIN, FENBENDAZOLE and MEBENDAZOLE (Triple therapy) Testimonial - 51 year old Engineer from CZECH REPUBLIC with Stage 4 NSCLC Lung Cancer Reports after 4 months - Oncologist is surprised! I just SHOCKED a CZECH Oncologist! STORY: 51 year old Engineer from Czech Republic with Stage 4 NSCLC Lung Cancer In September 2025 he started:
  • Ivermectin 1mg/kg/day
  • Fenbendazole 1000mg/day
  • Oncologist: Tagrisso 80mg
  • Mebendazole 1000mg/day added in December 2025
RESULTS after 4 months: Lung tumors shrinking. Bone metastases healing. From Patient: "his condition has significantly improved. Exactly as the doctor writes, the doctor was surprised and said that she did not expect this improvement and was sincerely happy".

Case 4 - 2025: 54 year old California woman with Stage 4 NSCLC Lung Cancer

Dr William Makis shared on X.com in December 2025:

IVERMECTIN, FENBENDAZOLE, CBD Oil Testimonial - 54 year old California woman with Stage 4 NSCLC Lung Cancer reports after 4 months - the results are stunning!

Some success stories leave your jaw on the floor.
TRIGGER WARNING - No chemo here!! 54 year old California woman with Stage 4 NSCLC Lung Cancer In early August 2025 she started taking:
  • Ivermectin 1mg/kg/day (48mg/day) 
  • Fenbendazole 1000mg/day (BP Life) 
  • CBD Oil 100mg/day 
  • Oncologist: Tagrisso 80mg/day (tyrosine kinase inhibitor) 
  • Radiation Oncologist: 10 day radiation treatment right hip, left deltoid.
Results after 3 months:
  • Primary RUL Tumor: 6.4x5.3cm to 3.5x2.3cm = 84% volume reduction.
  • Right hilar nodal mets = 100% resolution.
  • Mediastinal nodal mets: 3.2cm to 1.5cm = 90% volume reduction.
  • Soft tissue mets right proximal thigh, right hemipelvis, left subscapularis, right paraspinous = 100% resolution.
  • left upper arm lesion: 2.0cm to 1.3cm = 73% volume reduction.
The tumor shrinkage is nothing short of miraculous. The patient started with a HUGE tumor burden! 

This case shows synergy of Ivermectin + Fenbendazole + Tagrisso (targeted therapy).

Case 5 - 2025: 45-year-old UK woman with Stage 4 Non-Small Cell Lung Cancer with lymph node, liver and adrenal metastases

Dr William Makis shared on X/Twitter in April 2025:

IVERMECTIN and FENBENDAZOLE Testimonial - 45 year old UK woman with Stage 4 Non-Small Cell Lung Cancer with lymph node, liver and adrenal metastases, has 75% of disease gone after 4 months! Ready for a nice Stage 4 Lung Cancer story?  45 year old UK woman with Stage 4 NSCLC Lung Cancer with lymph node, liver, and adrenal metastases. In early September 2024 we started:
  • Ivermectin 1 to 2 mg/kg/day (eventually built up to 96mg Ivermectin a day, or 1.5mg/kg)
  • Fenbendazole 444mg a day
  • CBD Oil 25mg a day
  • Melatonin 120mg a day
Oncologist started Osimertinib (Tagrisso)

RESULTS (January 2025 PET/CT):
  • Adrenal metastasis shrunk from 6cm to 3.6cm
  • Lymph node metastases resolved
  • Liver metastases resolved
  • Oncologist estimated 75% of tumor burden had resolved.
The patient had some transient visual side effects with Ivermectin which are typical in the beginning but they went away.

"Liver completely cleared up" 
"Lymph lump in neck completely gone".

Case 6 - 2025: 40s year old California Man with Stage 4 Lung Cancer (Jan 2025 update)

Case testimonial from Dr William Makis (X/Twitter) in Jan 2025:

"IVERMECTIN and FENBENDAZOLE Testimonial - 40s year old California Man with Stage 4 Lung Cancer (post three Pfizer COVID-19 Vaccines, Turbo Cancer?) sees dramatic improvement in 3 months! Another wonderful story for you:

40s year old California man (who had three Pfizer COVID-19 mRNA Vaccines), was coughing for months, and was diagnosed with an unexpected Stage 4 Lung Cancer (NSCLC) metastatic to numerous lymph nodes and pleura, with a pleural effusion. We started an aggressive protocol: 
  • Ivermectin 1mg/kg/day increasing slowly to 2mg/kg/day (high dose!)
  • Fenbendazole 888mg/day
  • Oncologist also started Tagrisso (Osimertinib)
3 Months Later:
  • Primary lung tumor reduced in size from 3cm to 2cm.
  • Pleural effusion resolved completely (!)
  • Gained 15 pounds of weight from his lowest before he started the protocol. These are very significant improvements!"





Why This Protocol May Have Contributed – The Science (Our Hallmarks Lens)

Ivermectin and fenbendazole have demonstrated multiple anti-cancer mechanisms in preclinical lung cancer models:

- Ivermectin: Inhibits mitochondrial function, disrupts PAK1 signaling, and promotes apoptosis in cells with high proliferative signaling. It may also enhance the effects of EGFR-targeted therapies like osimertinib.  

- Fenbendazole: Acts as a microtubule disruptor (similar to some chemotherapies) and mitochondrial uncoupler, targeting the “deregulating cellular energetics” and “resisting cell death” hallmarks.  

- Synergy with Tagrisso: Osimertinib blocks mutant EGFR-driven growth; the repurposed agents add metabolic stress, potentially overcoming resistance pathways common in advanced lung cancer.  

These mechanisms align with the updated 2026 Hallmarks of Cancer (sustaining proliferative signaling, deregulating cellular energetics, resisting cell death). While large randomized trials are still lacking, the metabolic targeting + repurposed drug combination continues to appear in observational reports like this one.

Lessons for Readers

This case highlights a recurring theme in integrative oncology: when standard targeted therapies begin to plateau or when patients seek additional options, carefully monitored repurposed metabolic agents may contribute to meaningful radiographic and clinical responses — even in metastatic disease. However, rigorous monitoring (liver function, drug levels, imaging) is essential, and results remain highly individual.

Important Medical Disclaimer (Repeated)

This is not medical advice. Ivermectin and fenbendazole are not approved for cancer treatment. Never discontinue or replace approved therapies without specialist guidance. Liver monitoring and oncologist supervision are mandatory. Consult your physician.


Related References:
  1. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients
  2. Ivermectin and Fenbendazole or Mebendazole in Cancer: Peer-Reviewed Protocol in Cancer
  3. Ivermectin and Cancer: Anti-cancer Mechanisms of Action
  4. Fenbendazole and Cancer: Anti-Cancer Mechanisms of Action
  5. AI Predicts Ivermectin and Mebendazole Combined with Pembrolizumab, Adagrasib, Nutraceuticals, and Tailored Diet/Lifestyle Improved Overall Survival in Stage 4 Non Small Cell Lung Cancer
  6. Drug Repurposing for Cancer Therapy 2025: From AI-Driven Discovery to Practice-Changing Clinical Trials.
  7. Fenbendazole and Other Stage 4 Cancer Types: The compilation includes over 300 stage 4 cancer case reports across 17 cancer types. Full details are provided in the following: Stage 4 Cancer Remissions with Fenbendazole, Ivermectin and Mebendazole (2026 Edition).
  8. Fenbendazole, Ivermectin and Mebendazole Cancer Success Stories: 700+ Case Reports Compilation of various stages (stages 1 to 4) of different cancer types (2026 Edition). (One Day MD 2026)
  9. Tagrisso (osimertinib) for EGFR mutated NSCLC (YouTube 2022)
  10. Lung Cancer Research and Clinical Management in 2026: Precision Oncology, Immunotherapy, and Emerging Signals From Drug Repurposing (Cancer Advisor 2026)

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. Supporters point to hundreds of preclinical studies and case reports showing anti-tumor activity across multiple cancer types.  However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiotherapy. So where does the truth lie? The answer is more nuanced than either side often suggests. Access to modern cancer care remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings m...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

Image
Medically Reviewed | Last updated on June 28, 2026. Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. Repurposed Cancer Therapies Case Reports Explorer Interactive tracking dashboard compiling 766 reported case studies across 21 fields. Click any card to jump directly to its dedicated arti...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

Image
Quick Answer The supplements with the strongest human research behind them are vitamin D3 (paired with K2 and magnesium) , curcumin , omega-3 fatty acids , and green tea EGCG — each backed by multiple randomized controlled trials or meta-analyses, though results are mixed rather than uniformly positive. Melatonin looked promising in older, smaller trials, but the largest randomized trial to date found no overall survival benefit. No supplement replaces conventional cancer treatment, and a few — high-dose beta-carotene, vitamin E, and high-dose B6/B12 — have been linked to increased cancer risk in specific groups. Antioxidant supplements are generally discouraged during chemotherapy or radiotherapy unless a doctor directs otherwise. This is an educational overview, not personal medical advice — always loop in your oncology team before starting anything new. Disclosure: Some links in this article are affiliate links (including The Wellness Company and Amazon Associates). If ...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

Image
Last revised: July 2026 .  Integrative Oncology · Protocol Review A comprehensive synthesis of Dr Makis's clinical dosing regimens, benzimidazole combination strategies, the 2026 Hulscher observational cohort, pharmacokinetic rationale, safety monitoring requirements, and anonymised patient outcome data — presented with evidence grading. OneDayMD Editorial Team  |  Medically reviewed and updated  |  About Us Abstract Background: Dr William Makis MD (McGill Medicine; 110+ peer-reviewed publications) has treated cancer patients using repurposed antiparasitic agents since 2023, publicly documenting protocols and outcomes via Substack and X (@MakisMD). His approach centres on high-dose ivermectin combined with benzimidazoles and metabolic interventions, customised by cancer type and stage. Purpose: This continuously updated review synthesises Dr Makis's published p...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2026)

Image
Medically Reviewed by: OneDayMD Editorial Team | Evidence Synthesis & Safety Review | Last Updated: July 2026 Quick Answer Ivermectin, fenbendazole, and mebendazole are antiparasitic drugs with laboratory evidence of anticancer activity.  The pharmacological rationale is real and merits continued, properly controlled trial investment. Patients should discuss any interest in these agents openly with their oncology team rather than self-administering veterinary or compounded formulations.  This article separates the genuine research question from the unverified claims, and outlines what to discuss with an oncology team before considering any of these agents. Background: Ivermectin and the benzimidazole anthelmintics fenbendazole and mebendazole have attracted sustained public attention as repurposed anticancer agents, driven substantially by social media case testimonials and a small number of peer-reviewed mechanistic studies. Objective: To synthesize the preclin...
Read more

30 Best Alternative Cancer Treatments 2026: Proven Interventions

Image
Updated July 2026 · Evidence-Ranked Edition This article has been reorganised to rank all 30 integrative cancer interventions by the quality and quantity of available evidence — from randomised controlled trial data down to preclinical laboratory findings. Use this as a structured reference, not a treatment guide. Always consult a qualified healthcare professional before initiating any therapy. ⚠️ Medical Disclaimer: This content is for educational purposes only. Nothing in this article should be used as the basis for initiating, modifying, or discontinuing any cancer treatment without guidance from your treating oncologist or physician. The interventions described here are not approved cancer treatments unless explicitly stated. Diverse cancer hallmarks targeted by repurposed non-oncology drugs. Source: Nature 2024 Introduction Most mainstream guides to “alternative cancer treatments”—including the widely cited Mayo Clinic overview—focu...
Read more

Fenbendazole, Ivermectin and Mebendazole for Stage 4 Pancreatic Cancer: A Compilation of Case Reports and Mechanistic Insights (2026)

Image
OneDayMD  |  Integrative Oncology Review ISSN (Online) pending  •  Volume 1, Issue 1  •  Published: 10 August 2025  •  Last updated: 15 July 2026 Case Series & Mechanistic Review Compiled tumour marker responses, radiologic outcomes, and mechanisms of anti-cancer action across an international patient cohort DOI: pending  •  Cite as: OneDayMD Editorial Team. Antiparasitic Drug Repurposing in Stage 4 PDAC: A Compiled Case Series of 28 Patients. OneDayMD Integr Oncol Rev. 2025;1(1). Updated July 2026. Evidence Classification All case reports in this series represent CEBM Level 4–5 evidence (case reports and expert opinion). This compilation is hypothesis-generating. No randomised controlled trials of ivermectin, fenbendazole, or mebendazole for pancreatic cancer have been published as of July 2026. ...
Read more

Archive

Show more